Corbus Pharmaceuticals Holdings, Inc. filings document a clinical-stage biotechnology issuer focused on oncology and obesity. The record includes Form 8-K material-event reports for clinical and regulatory disclosures involving CRB-701 and CRB-913, Regulation FD corporate presentations and risk language tied to product development, trial timelines and business strategy.
Proxy and governance filings cover board matters, executive compensation, equity awards, employment agreements and officer or director changes. The filings also provide formal disclosure categories for operating and financial results and the governance framework supporting the company’s drug-development pipeline.
Corbus Pharmaceuticals Holdings, Inc. director Brent Pfeiffenberger filed an initial ownership report on Form 3. The filing lists him as a director of the company but does not report any share transactions or holdings in this snapshot, serving as a baseline disclosure of his insider status.
Corbus Pharmaceuticals Holdings, Inc. has entered a two‑year employment agreement with Nishant Saxena, appointing him as Chief Business Officer effective May 21, 2026. His package includes a $470,000 base salary, a target bonus up to 40% of salary, and sizable stock‑based incentives.
Saxena will receive 192,300 stock options and 58,300 restricted stock units, with multi‑year vesting and enhanced severance and equity acceleration if he is terminated without cause or leaves for good reason, particularly around a change in control. The company also granted director Brent Pfeiffenberger 24,700 options and 7,500 RSUs under its 2024 Equity Incentive Plan.
Corbus announced a May 26, 2026 conference call and webcast to discuss updated Phase 1/2 data for its Nectin‑4 antibody‑drug conjugate CRB‑701 in head and neck squamous cell carcinoma and cervical cancer, ahead of presentations at the 2026 ASCO Annual Meeting.
Corbus Pharmaceuticals Holdings, Inc. Schedule 13G/A Amendment No. 2 reports that Octagon Capital Advisors LP, Octagon Investments Master Fund LP and Ting Jia jointly report 0 shares beneficially owned, representing 0.0% of Common Stock based on 17,736,464 Common Shares outstanding as of March 23, 2026. The filing states Octagon is the Master Fund's investment manager and Dr. Jia is Octagon's managing member; the Master Fund holds any Common Shares for the benefit of its investors. Signatures are dated May 14, 2026.
Corbus Pharmaceuticals Holdings, Inc. appointed Brent Pfeiffenberger to its Board of Directors, expanding the board to seven members. He is considered independent under Nasdaq rules and will receive a $40,000 annual cash retainer, pro-rated, plus equity awards under the company’s standard non-employee director plan.
Stockholders approved an amendment to the 2024 Equity Compensation Plan to increase the shares of common stock authorized for issuance by 3,000,000 to 5,000,000, and also ratified EisnerAmper LLP as auditor, approved executive compensation on an advisory basis, and chose an annual say-on-pay vote. A press release highlighted upcoming data for oncology candidate CRB-701 and obesity candidate CRB-913, including a planned registrational study for CRB-701 and a 240-patient Phase 1b CANYON-1 study for CRB-913 expected to complete in summer 2026.
Corbus Pharmaceuticals Holdings reported a first-quarter 2026 net loss of $22.97 million, compared with $16.98 million a year earlier, as it advanced its oncology and obesity pipeline. Operating expenses rose to $24.30 million, driven mainly by higher research and development spending.
Research and development expense increased to $19.82 million, largely reflecting Phase 1/2 work on Nectin-4–targeting ADC CRB-701 and Phase 1b obesity study CANYON‑1 for CRB-913. Corbus ended March 31, 2026 with cash, cash equivalents and investments of about $138.2 million, which it expects to fund operations for at least 12 months, supported by a new $300 million shelf registration and remaining capacity under its at-the-market equity program.
Corbus Pharmaceuticals reported first-quarter 2026 results and highlighted progress in its oncology and obesity pipelines. The company posted a net loss of about $23.0 million, or $1.23 per share, on operating expenses of $24.3 million, primarily from higher clinical development spending. Cash, cash equivalents and investments totaled $138.2 million as of March 31, 2026, which Corbus expects will fund operations into 2028.
Corbus reached broad alignment with the FDA on the registration path for CRB-701 in second-line head and neck squamous cell carcinoma and cervical cancer and plans to start a registrational study in second-line HNSCC this summer, with updated monotherapy data to be presented at ASCO 2026. The company also completed enrollment and first visits in its CANYON-1 Phase 1b obesity trial of CRB-913, a peripherally restricted oral CB1 inverse agonist, and expects 16-week data from 240 patients in summer 2026.
Corbus Pharmaceuticals Holdings, Inc. updated its executive employment agreements for CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026, with terms running through April 15, 2028. Dr. Cohen will receive a base salary of $673,625 with a target bonus of up to 60% of salary, while Mr. Moran will receive $501,273 with a target bonus of up to 40%.
Both executives remain eligible for discretionary equity awards under the company’s equity incentive plans and are subject to non-compete and non-solicitation covenants after employment ends. If terminated without cause or for good reason, each is entitled to cash severance, COBRA reimbursement, and potential pro-rated bonuses, with enhanced cash, bonus, COBRA and full equity vesting protection during a defined change in control period, subject to signing a release and possible reduction to mitigate excise taxes under Section 4999.
Corbus Pharmaceuticals Holdings, Inc. reports that the last patient has been enrolled and completed the first clinical visit in its CANYON-1 Phase 1b trial of CRB-913 for obesity, keeping the study on track for completion in summer 2026. CANYON-1 is a 16-week, double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic participants at multiple U.S. sites. The trial tests once-daily oral CRB-913 at 20 mg, 40 mg, and 60 mg with dose titration from 20 mg, followed by one month of post-dosing monitoring. Earlier Phase 1a data showed CRB-913-treated obese participants achieved a mean 2.9% placebo-adjusted weight loss by Day 14 at 150 mg/day and the drug was reported as safe and well-tolerated, with a favorable gastrointestinal and neuropsychiatric profile.
Corbus Pharmaceuticals Holdings, Inc. announced broad alignment with the U.S. Food and Drug Administration on the registration path for CRB-701, its Nectin-4–targeting antibody drug conjugate, in second-line head and neck squamous cell carcinoma and cervical cancer. The agreed plans call for single, randomized controlled registrational studies in each indication, comparing CRB-701 to physicians’ choice chemotherapy or chemotherapy/Tivdak, with potential accelerated approval based on objective response rate and potential full approval based on overall survival.
The FDA has granted two Fast Track designations to CRB-701 in head and neck squamous cell carcinoma and cervical cancer. Updated Phase 1/2 monotherapy data will be presented at ASCO 2026, and the company anticipates reporting first-line HNSCC combination data with Keytruda in Q4 2026. Corbus expects to initiate a registrational study in second-line HNSCC in mid-2026. The company also disclosed that Chief Medical Officer Dr. Dominic Smethurst will step down effective June 30, 2026, as it adds new senior leaders for the next development phase.